$0.93
-0.03 (-3.14%)
Open$0.90
Previous Close$0.96
Day High$0.93
Day Low$0.85
52W High$3.68
52W Low$0.68
Volume—
Avg Volume16.0K
Market Cap10.77M
P/E Ratio—
EPS$-0.34
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,528.1% upside
Current
$0.93
$0.93
Target
$24.31
$24.31
$15.00
$24.31 avg
$29.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 329.8K | 1.99M | 1.82M |
| Net Income | -4,040,023 | -271,887 | -219,394 |
| Profit Margin | -1,227.1% | -13.7% | -12.0% |
| EBITDA | -3,647,604 | -443,981 | -374,843 |
| Free Cash Flow | — | -242,138 | -341,295 |
| Rev Growth | — | +6.4% | +1.5% |
| Debt/Equity | 0.07 | 0.27 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |